CL2019001046A1 -
Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
- Google Patents
Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen IncfiledCriticalAmgen Inc
Publication of CL2019001046A1publicationCriticalpatent/CL2019001046A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UNA TERAPIA DE COMBINACIÓN QUE INCLUYE UN INHIBIDOR MDM2 Y UNO O MÁS AGENTES FARMACÉUTICAMENTE ACTIVOS ADICIONALES, PARTICULARMENTE PARA EL TRATAMIENTO DE DISTINTOS TIPOS DE CÁNCER. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE CONTIENE UN INHIBIDOR MDM2 Y UNO O MÁS AGENTES FARMACÉUTICAMENTE ACTIVOS ADICIONALES PARA EL TRATAMIENTO DE CÁNCERES.THIS INVENTION PROVIDES A COMBINATION THERAPY THAT INCLUDES AN MDM2 INHIBITOR AND ONE OR MORE PHARMACEUTICALLY ACTIVE ADDITIONAL AGENTS, PARTICULARLY FOR THE TREATMENT OF DIFFERENT TYPES OF CANCER. THE INVENTION ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS CONTAINING AN MDM2 INHIBITOR AND ONE OR MORE PHARMACEUTICALLY ACTIVE ADDITIONAL AGENTS FOR THE TREATMENT OF CANCER.
CL2019001046A2014-11-112019-04-17
Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
CL2019001046A1
(en)
Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
Use of a pharmaceutical combination comprising an mdm2 inhibitor compound and one or more additional active agents for the treatment of cancer and pharmaceutical compositions comprising said combinations.
Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)